Royal Bank of Canada Has $440,000 Stake in Sarepta Therapeutics, Inc. (SRPT)

Royal Bank of Canada lessened its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 28.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,052 shares of the biotechnology company’s stock after selling 5,104 shares during the period. Royal Bank of Canada’s holdings in Sarepta Therapeutics were worth $440,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. BlackRock Inc. grew its holdings in Sarepta Therapeutics by 4,403.1% in the first quarter. BlackRock Inc. now owns 5,292,729 shares of the biotechnology company’s stock valued at $156,664,000 after purchasing an additional 5,175,193 shares during the period. Vanguard Group Inc. grew its holdings in Sarepta Therapeutics by 4.0% in the second quarter. Vanguard Group Inc. now owns 4,259,029 shares of the biotechnology company’s stock valued at $143,572,000 after purchasing an additional 162,543 shares during the period. HealthCor Management L.P. grew its holdings in Sarepta Therapeutics by 31.1% in the second quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock valued at $68,495,000 after purchasing an additional 481,890 shares during the period. Emerald Advisers Inc. PA grew its holdings in Sarepta Therapeutics by 6.9% in the second quarter. Emerald Advisers Inc. PA now owns 875,407 shares of the biotechnology company’s stock valued at $29,510,000 after purchasing an additional 56,702 shares during the period. Finally, Eagle Asset Management Inc. grew its holdings in Sarepta Therapeutics by 33.4% in the second quarter. Eagle Asset Management Inc. now owns 798,412 shares of the biotechnology company’s stock valued at $26,914,000 after purchasing an additional 200,103 shares during the period. 67.76% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Royal Bank of Canada Has $440,000 Stake in Sarepta Therapeutics, Inc. (SRPT)” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://sportsperspectives.com/2017/11/15/royal-bank-of-canada-has-440000-stake-in-sarepta-therapeutics-inc-srpt.html.

A number of equities research analysts recently issued reports on the stock. William Blair restated an “outperform” rating on shares of Sarepta Therapeutics in a report on Monday, October 2nd. Nomura restated a “buy” rating and issued a $84.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, September 5th. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $76.00 target price on shares of Sarepta Therapeutics in a report on Thursday, September 7th. Needham & Company LLC restated a “buy” rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a report on Wednesday, September 6th. Finally, Robert W. Baird restated an “outperform” rating and issued a $101.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 2nd. One analyst has rated the stock with a sell rating, six have issued a hold rating and sixteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $63.59.

Shares of Sarepta Therapeutics, Inc. (SRPT) opened at $54.79 on Wednesday. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.44 and a quick ratio of 9.52. Sarepta Therapeutics, Inc. has a twelve month low of $26.26 and a twelve month high of $57.57.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.66. The firm had revenue of $45.95 million for the quarter, compared to analysts’ expectations of $41.29 million. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. During the same period in the prior year, the company posted ($0.95) earnings per share. research analysts forecast that Sarepta Therapeutics, Inc. will post -3.11 EPS for the current year.

In other Sarepta Therapeutics news, CEO Douglas S. Ingram bought 38,138 shares of the company’s stock in a transaction on Wednesday, November 8th. The shares were bought at an average cost of $52.44 per share, with a total value of $1,999,956.72. Following the completion of the acquisition, the chief executive officer now owns 420,196 shares of the company’s stock, valued at $22,035,078.24. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Shamim Ruff sold 10,000 shares of the stock in a transaction on Monday, November 6th. The stock was sold at an average price of $55.00, for a total transaction of $550,000.00. Following the sale, the senior vice president now directly owns 37,045 shares in the company, valued at $2,037,475. The disclosure for this sale can be found here. Corporate insiders own 9.60% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply